330 related articles for article (PubMed ID: 33669443)
1. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
Hajduch E; Lachkar F; Ferré P; Foufelle F
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
[TBL] [Abstract][Full Text] [Related]
2. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
Régnier M; Polizzi A; Guillou H; Loiseau N
Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
[TBL] [Abstract][Full Text] [Related]
4. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
[TBL] [Abstract][Full Text] [Related]
5. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
Yu XD; Wang JW
Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.
Jiang M; Li C; Liu Q; Wang A; Lei M
Front Endocrinol (Lausanne); 2019; 10():665. PubMed ID: 31616384
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
[TBL] [Abstract][Full Text] [Related]
8. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
9. Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
[TBL] [Abstract][Full Text] [Related]
12. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
[TBL] [Abstract][Full Text] [Related]
13. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
14. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
[TBL] [Abstract][Full Text] [Related]
15. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipids at the Crossroads of NAFLD and Senescence.
Nikolova-Karakashian M
Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
[TBL] [Abstract][Full Text] [Related]
17. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
18. Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.
Apostolopoulou M; Gordillo R; Gancheva S; Strassburger K; Herder C; Esposito I; Schlensak M; Scherer PE; Roden M
BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33219119
[TBL] [Abstract][Full Text] [Related]
19. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics in non-alcoholic fatty liver disease.
Lee J; Kim Y; Friso S; Choi SW
Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
